Pfizer, Astellas Report Xtandi Survival Win In Prostate Cancer Study

benzinga.com/markets/biotech/25/07/46352807/pfize-astellas-report-xtandi-survival-win-in-prostate-cancer-study

Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (OTC:ALPMF) (OTC:ALPMY) on Thursday released topline results from the overall survival (OS) analysis from the Phase 3 EMBARK study evaluating Xtandi (enzalutamide), in combination with leuprolide and as a monotherapy, in men with…

This story appeared on benzinga.com, 2025-07-10 18:49:05.
The Entire Business World on a Single Page. Free to Use →